Abstract
Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Anti-Cancer Agents in Medicinal Chemistry
Title: The Bright Future of Radionuclides for Cancer Therapy
Volume: 7 Issue: 3
Author(s): Johannes Franciscus Wilhelmus Nijsen, Gerard Cornelis Krijger and Afred Dirk van het Schip
Affiliation:
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Abstract: Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Export Options
About this article
Cite this article as:
Franciscus Wilhelmus Nijsen Johannes, Cornelis Krijger Gerard and Dirk van het Schip Afred, The Bright Future of Radionuclides for Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618207
DOI https://dx.doi.org/10.2174/187152007780618207 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches
Recent Patents on Biotechnology The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Meet Our Regional Editor
Current Nutrition & Food Science Qualitative Estimation of Drug Entrapment Efficiency in Polymeric Nano - Micelles Using Dissipative Particle Dynamics (DPD)
Pharmaceutical Nanotechnology An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Evaluation of Adhesion Force and Binding Affinity of Phytohemagglutinin Erythroagglutinating to EGF Receptor on Human Lung Cancer Cells
Current Medicinal Chemistry Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials High Throughput Screening of Genetic Polymorphisms by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
Combinatorial Chemistry & High Throughput Screening Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Calcium and Zinc DTPA Administration for Internal Contamination with Plutonium-238 and Americium-241
Current Pharmaceutical Biotechnology Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition
Combinatorial Chemistry & High Throughput Screening Aptamers Overview: Selection, Features and Applications
Current Topics in Medicinal Chemistry Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Editorial (Thematic Issue : Recent Advances in Cancer Research: Targets and New Ligands)
Current Pharmaceutical Design